Trial in Progress: Real-World Safety and Effectiveness of Brentuximab Vedotin in Adults with CD30+Lymphoma in China

被引：0
|
作者：
Xu, Pengpeng [1 ]
Cai, Mingci [1 ]
Zhang, Wendy [2 ]
Zhao, Wei Li [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom, Shanghai Inst Hematol,Ruijin Hosp,Sch Med, Shanghai, Peoples R China
[2] Takeda China Int Trading Co Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-149031
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4552
引用
收藏
页数：2
相关论文
共 50 条
  • [11] BRENTUXIMAB VEDOTIN FOR THE TREATMENT OF HODGKIN LYMPHOMA AND CD30+NON HODGKIN LYMPHOMA: A MULTICENTER TUSCANY EXPERIENCE OUTSIDE CLINICAL TRIAL
    Mannelli, L.
    Cecconi, N.
    Iovino, L.
    Galimberti, S.
    Puccini, B.
    Fabbri, A.
    Cencini, E.
    Kovalchuk, S.
    Occhini, U.
    Della Seta, R.
    Stefanelli, A.
    Birtolo, S.
    Bernardeschi, P.
    Riccioni, R.
    Petrini, M.
    Bosi, A.
    Rigacci, L.
    HAEMATOLOGICA, 2017, 102 : 106 - 106
  • [12] REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN VS OTHER TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA POST AUTOLOGOUS STEM-CELL TRANSPLANTATION
    Zagadailov, E. A.
    Corman, S.
    Hagan, M.
    Chirikov, V.
    Johnson, C.
    Macahilig, C.
    Sea, B.
    Dalal, M. R.
    Broeckelmann, P. J.
    Illidge, T.
    HAEMATOLOGICA, 2016, 101 : 51 - 51
  • [13] Brentuximab a novel antibody therapy: real-world use confirms efficacy and tolerability for CD30-positive cutaneous lymphoma
    Engelina, S.
    Saggu, M.
    Yoo, J.
    Shah, F.
    Stevens, A.
    Irwin, C.
    Chaganti, S.
    Scarisbrick, J. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (03) : 799 - 800
  • [14] Trial in Progress: A Phase 4 Multicenter Study of Brentuximab Vedotin Treatment in Chinese Patients with CD30Positive Cutaneous T-Cell Lymphoma
    Wang, Qian
    Jiang, Ming
    Zhang, Chunlei
    Wu, Sheng
    Jiang, Wenhan
    Ji, Meng
    Chen, Tong
    BLOOD, 2022, 140 : 12044 - 12045
  • [15] Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+T cell lymphoma
    Oberic, Lucie
    Delzor, Faustine
    Protin, Caroline
    Perriat, Sophie
    Laurent, Camille
    Grand, Anais
    Canonge, Jean Marie
    Borel, Cecile
    Gauthier, Martin
    Ysebaert, Loic
    Puisset, Florent
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (07) : 1730 - 1735
  • [16] Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
    Duvic, Madeleine
    Tetzlaff, Michael T.
    Gangar, Pamela
    Clos, Audra L.
    Sui, Dawen
    Talpur, Rakhshandra
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3759 - +
  • [17] Efficacy and Safety of Retreatment with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or CD30-Expressing Peripheral T Cell Lymphoma
    Sano, Dahlia
    Ahmed, Sairah
    Liu, Jingmin
    Knowles, Scott
    Lee, Seung Tae
    BLOOD, 2022, 140 : 12003 - 12004
  • [18] Real-World Study Evaluating the Efficacy of Frontline Brentuximab Vedotin Plus Chemotherapy in Newly Diagnosed Patients with Hodgkin Lymphoma: A Retrospective Analysis
    Cai, Qingqing
    Xia, Yi
    Liu, Panpan
    Zhang, Yuchen
    Zou, Qihua
    Cai, Jun
    BLOOD, 2022, 140 : 12035 - 12036
  • [19] Brentuximab-vedotin in CTCL with low CD-30 expression - "Real-life" Data of the German Cutaneous Lymphoma Network
    Blazejak, C.
    Stranzenbach, R.
    Hillen, U.
    Mitteldorf, C.
    Nicolay, J. P.
    Wobser, M.
    Schruefer, P.
    Gosmann, J.
    Stadler, R.
    Wehkamp, U.
    Stendel, S.
    Booken, N.
    Kreuter, A.
    Dippel, E.
    Klemke, C. -D
    Assaf, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 90 - 90
  • [20] Brentuximab Vedotin and Bendamustine Combination Therapy as Salvage for Relapsed-Refractory Hodgkin Lymphoma: A Real-World Single-Center Experience
    Bajaj, Rajat
    Radhakrishnan, Vivek
    Bhave, Saurabh
    Kumar, Jeevan
    Arora, Neeraj
    Dey, Debdeep
    Parihar, Mayur
    Mishra, Deepak
    Chandy, Mammen
    Nair, Reena
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S246 - S247
12345